Immunome, Inc.
Immunome announces $400 million follow-on public offering.
1 source·17/12, 21:50·sec.gov
Positive Phase 3 trial results for varegacestat announced.
1 source·15/12, 12:06·sec.gov
10-Q form submitted!
1 source·06/11, 21:24·sec.gov
Company announces Q3 2025 financial results update.
1 source·06/11, 21:22·sec.gov
10-Q form submitted!
1 source·06/08, 20:21·sec.gov
Immunome announces Q2 2025 financial results.
1 source·06/08, 20:18·sec.gov
Routine voting results from annual stockholders meeting.
1 source·11/06, 20:04·sec.gov
Analysts predict significant upside potential for Immunome.
1 source·26/05, 14:57·finviz.com
Immunome to present at investor conferences.
1 source·22/05, 12:07·businesswire.com
Immunome upgraded to Zacks Rank #2, indicating buy potential.
1 source·13/05, 17:04·finviz.com
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
·finviz.com·26/05, 14:57
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
·businesswire.com·12/05, 20:13
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
·businesswire.com·02/05, 20:16